MannKind (NASDAQ: MNKD) reported Q4 EPS of ($0.06), versus ($0.28) reported last year. Revenue for the quarter came in at $16 million, versus $4.5 million reported last year. Afrezza net revenue was $5.7 million and collaboration and services revenue of $10.3 million.

The company achieved first-ever quarterly Afrezza gross profit in 4Q 2018.

“Our fourth quarter and full year 2018 results showed excellent progress in executing against our Afrezza growth plan and recognized for the first time revenues associated with our license and collaboration agreement with United Therapeutics,” said Michael Castagna, Chief Executive Officer of MannKind Corporation. “The fourth quarter of last year was the first time we reported gross profit for Afrezza and we ended the year with a strong cash position thanks to the United Therapeutics deal and a public offering of common stock and warrants in December.”

For earnings history and earnings-related data on MannKind (MNKD) click here.